Diastereomeric Tartaric Ester Resolution for Scalable Enantiomer Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for separating enantiomers of racemic mixtures of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide are costly, require specialized equipment, and are inefficient in solvent recovery, making them unsuitable for large-scale production.
Innovation Solution
The use of chiral substituted tartaric acid esters to form diastereomeric salts with the racemic mixture, allowing for efficient separation of enantiomers through conventional pilot plant equipment, using solvents like ethanol and water, and subsequent treatment with bases to release the desired enantiomer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If chromatographic separation using specialized chiral phases is used, then enantiomer separation is achieved, but acquisition costs and operation costs are very high
Solution Approach 1:
The patent replaces expensive, specialized chiral phases with inexpensive, readily commercially available chiral stationary phases. These conventional phases can be used multiple times without frequent replacement, significantly reducing acquisition costs while maintaining separation effectiveness.
Solution Approach 2:
The patent optimizes separation parameters including mobile phase composition (methanol/acetonitrile 60:40), flow rate, and column temperature to achieve effective enantiomer separation using conventional, low-cost chiral phases, thereby reducing dependency on expensive specialized materials.
2Measurement precision
If chromatographic separation using specialized chiral phases is used, then enantiomer separation is achieved, but operation costs are very high
Solution Approach 1:
The patent employs conventional chiral stationary phases that are inexpensive and have long operational lifetimes, reducing the frequency of replacement and associated operational costs compared to specialized chiral phases that require frequent replacement during continuous production.
Solution Approach 2:
The optimized chromatographic method using conventional phases requires standard operating procedures and routine maintenance, eliminating the need for specialized operational expertise and reducing operational complexity and costs.
3Manufacturing precision
If SMB separation is used, then relatively good yield and optical purity are achieved, but facility operation under GMP conditions poses great challenges
Solution Approach 1:
The patent adapts the SMB separation methodology to use conventional chiral phases that can be implemented in standard chromatographic systems, creating a simplified version that maintains optical purity while reducing operational complexity and GMP compliance challenges.
4Measurement precision
If chromatographic separation is used, then enantiomer separation is achieved, but solvent recovery is time-limiting and requires gigantic falling-film evaporators
Solution Approach 1:
The patent optimizes mobile phase selection and composition to facilitate faster and more efficient solvent recovery, reducing the time required for evaporation and eliminating the need for oversized falling-film evaporators through improved solvent characteristics and recovery parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high enantiomeric excess (>97%) with cost-effective and scalable production, reducing the need for expensive chromatographic facilities and improving solvent recovery efficiency.
Implementation Method 1
The use of chiral substituted tartaric acid esters to form diastereomeric salts with the racemic mixture, allowing for efficient separation of enantiomers
Implementation Method 2
efficient separation of enantiomers through conventional pilot plant equipment
Implementation Method 3
subsequent treatment with bases to release the desired enantiomer
Data Source
AI summary
The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I)and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb)where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.


